Cancer Genetics, Inc., used this week’s annual United States & Canadian Academy of Pathology (USCAP) conference as a forum to announce new data that the company says further validates its UroGenRA-Kidney diagnostic test for renal cell cancer. The new data was generated as part of a collaborative study conducted with the Cleveland Clinic in which 191 pathology specimens from renal cancer patients were provided and analyzed using the UroGenRA-Kidney test.
On March 3, Cristina Magi-Galluzzi, MD, PhD, of the Cleveland Clinic gave a podium presentation entitled “Evaluation of a Decision Tree in the Diagnosis of Renal Neoplasms Based on Genomic Aberrations Detected by Array-CGH” in which she provided an overview of CGI’s UroGenRA-Kidney test and its ability to classify kidney cancer among the four major subtypes and predict whether the cancer is benign or malignant. The test has been validated to work across sample types ranging from fine-needle aspirate to paraffin-embedded and formalin-fixed tissue, making it widely usable for both new cases and cases that are not diagnosable using traditional methods.
CGI plans to share the details of the 191-patient study as well as information on the test’s sensitivity, specificity, and clinical use. More than 60,000 new cases of kidney cancer are detected each year in the U.S., and approximately 14,000 deaths occur, making more accurate diagnosis and earlier time to treatment critical in managing kidney cancer.
